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Introduction {#sec1}
============

Immune checkpoint therapies including those targeting PD-1, or its primary ligand PD-L1, have demonstrated therapeutic responses across a broad range of cancer types ([@bib39]). Anti-PD-1 therapy blocks the interaction of PD-1, an inhibitory receptor on tumor-infiltrating T cells, with its ligands PD-L1 and PD-L2 that are predominantly expressed on tumor cells and antigen-presenting cells (APCs), respectively ([@bib45]). Despite the success of anti-PD-1 immunotherapy in approximately 20%--30% of patients with cancer, the majority of patients do not respond to this treatment ([@bib40]). In addition, increasing clinical evidence suggests that a significant subset of nonresponsive patients may experience acceleration of disease progression after treatment with anti-PD-1, a phenomenon known as hyperprogressive disease (HPD). Although accurate identification of the frequency of patients developing HPD has been limited by variability in diagnostic criteria, conservative estimates suggest that HPD may occur in as many as 10% of patients treated with anti-PD-1 ([@bib5], [@bib22], [@bib37]).

In contrast to identifying factors that predict responsiveness to PD-1-blocking therapies such as tumor expression of PD-L1, high tumor mutational burden, and the presence of tumor-infiltrating CD8+ T cells, little is known about the mechanisms underlying HPD. Although a pilot study suggested that some patients with *MDM2* family amplification or *EGFR* aberrations developed HPD after treatment with PD-1 or PD-L1 inhibitors ([@bib22]), it is likely that alterations beyond those identified in that study are important in facilitating accelerated disease progression.

To comprehensively examine the mechanisms of HPD, we performed whole-exome sequencing (WES) and RNA sequencing (RNA-seq) analyses of formalin-fixed paraffin-embedded (FFPE) samples of tumors before and after anti-PD-1 therapy in patients with clinical evidence of HPD. We identified individual somatic mutations and mutation clusters associated with clonal evolution that may contribute to the accelerated tumor growth observed in HPD. We also identified characteristic decreases in HPD tumor immunogenicity. Finally, we identified a gene signature that may be predictive of HPD development. These changes were HPD patient specific, and were not found in the tumors of anti-PD-1-treated patients without HPD phenotypes from previous studies. Overall, our study identified the genomics and immune features associated with HPD tumors after anti-PD-1 immunotherapy.

Results {#sec2}
=======

Mutation Patterns Are Altered in HPD Tumors after Anti-PD-1 Treatment {#sec2.1}
---------------------------------------------------------------------

This study included two patients who received anti-PD-1 blockade immunotherapy. Relevant characteristics of the four FFPE tumor samples are summarized in [Table 1](#tbl1){ref-type="table"}. Paired tumor samples before and after anti-PD-1 treatment were obtained from a male patient with esophageal squamous cell carcinoma metastatic to lymph nodes (Patient 1) and from a female patient with clear cell renal cell cancer (ccRCC) that had metastasized to the bone (shoulder) and pleura (Patient 2). Following anti-PD-1 treatment that consisted of pembrolizumab (Merck), these two patients demonstrated HPD, as defined by the accelerated tumor growth rate and clinical deterioration using existing criteria ([@bib22]). Each patient demonstrated progression at first radiologic evaluation (less than 2 months after anti-PD-1 therapy initiation). Before enrollment, written informed consent was obtained from all patients to use their tumor samples for research purposes. The study was approved by the Medical College of Wisconsin Institutional Review Board in accordance with federal regulations.Table 1Characteristics of the Four FFPE Specimens from Two Patients, Consisting of Paired Pre- and Post-anti-PD-1 (Pembrolizumab) Treatment SamplesPatientGenderSpecimenCancerTreatmentOther Clinical Phenotype% Tumor\#1MaleS1624794Esophageal squamous cell carcinomaPre-anti-PD-1Metastatic to lymph node75S1707359Esophageal squamous cell carcinomaPost-anti-PD-1Metastatic to lymph node75\#2FemaleM16248Clear cell renal cell carcinomaPre-anti-PD-1Metastatic to the pleura and shoulder50S1701860Clear cell renal cell carcinomaPost-anti-PD-1Metastatic to the pleura and shoulder75

To understand the global changes that take place in HPD tumors after treatment with anti-PD-1, we performed mutational analysis on tumors obtained before and after treatment with pembrolizumab. We observed that Patient 1 had 195 somatic mutations before anti-PD-1 treatment and 338 somatic mutations after treatment; Patient 2 had 156 somatic mutations before treatment and 251 somatic mutations after treatment ([Table S1](#mmc2){ref-type="supplementary-material"}). There were 154 and 124 common somatic mutations shared by the HPD and pre-therapy tumors for Patients 1 and 2, respectively ([Figure S1](#mmc1){ref-type="supplementary-material"}). Our results were in line with another group\'s results showing increased tumor mutation load from baseline in PD (progressive disease) in patients with melanoma after anti-PD-1 therapy (nivolumab) initiation ([@bib35]). In the latter, the tumor mutation load was decreased in the responding patients (complete response/partial response) from baseline since nivolumab initiation, consistent with immunoediting ([@bib35]). We also analyzed the mutation profiles of these two patients in the context of known cancer genes based on a comprehensive list of cancer-related genes (downloaded from <http://www.bushmanlab.org/links/genelists>). There were 47 cancer genes mutated in at least one of the tumors from Patient 1 and 40 cancer genes mutated in at least one of the tumors from Patient 2 ([Figure 1](#fig1){ref-type="fig"}, [Table S2](#mmc3){ref-type="supplementary-material"}). Four cancer genes (*APH1A*, *ARHGEF12*, *GPER1*, and *KIF14*) mutated in the pre-therapy tumor of Patient 1 were not mutated in the HPD tumors, suggesting that the tumor clones containing these four cancer genes were eliminated by anti-PD-1 treatment. However, the HPD tumor of Patient 1 had somatic mutations in 20 cancer genes, including *IGFBP2*, *KMT2C*, *MAP3K4*, *MUC16*, *MUC2*, *NCOR2*, and *NOTCH4*, which were not present in the pre-therapy tumors. Similar patterns were also observed for Patient 2. Four cancer genes (*APC2*, *OBSCN*, *PHLPP1*, and *SATB1*) that were mutated in the pre-therapy tumor of Patient 2 were not mutated in the post-treatment tumors, whereas the HPD tumor of Patient 2 had somatic mutations in 21 cancer genes, including *IGFBP2*, *MUC4*, *NCOR2*, *NFE2L2*, *TSC2*, and *VHL*, which were not present in the pre-therapy tumors. The identified mutations in these genes were not present in the tumors of non-HPD patients after anti-PD-1 treatment when compared with previous studies ([@bib2], [@bib14], [@bib16], [@bib19], [@bib31], [@bib35], [@bib36], [@bib44], [@bib51], [@bib52]). These data indicate that the mutational landscape of tumors was significantly altered after anti-PD-1 therapy in patients who demonstrated hyperprogression after anti-PD-1 treatment.Figure 1Profiles of Mutated Cancer Genes (Nonsilent Somatic Mutations) in the Pre- and Post-anti-PD-1 Treatment Tumor Samples(A) Mutation pattern of Patient 1.(B) Mutation pattern of Patient 2. Indel: insertions or deletions.See also [Figure S1](#mmc1){ref-type="supplementary-material"}, [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

For comparison in the context of corresponding cancer populations, we analyzed the numbers of somatic mutations of the esophageal carcinoma (ESCA, n = 184) and kidney renal clear cell carcinoma (KIRC, n = 384) samples from The Cancer Genome Atlas (TCGA). The numbers of nonsilent somatic mutations were in the range of 4--1,763 for ESCA and 15--1,349 for KIRC. The lower quartile, median, and upper quartile were 85, 110, and 168 for ESCA and 54, 77, and 109 for KIRC, respectively ([Figure S2](#mmc1){ref-type="supplementary-material"}). The numbers of nonsilent somatic mutations in the before and after anti-PD-1 therapy tumors of the two HPD patients in this study were 195 and 338 for the patient with ESCA and 156 and 251 for the patient with KIRC. Therefore, they were all above the upper quartiles of TCGA ESCA and KIRC datasets, which suggested that these two patients have an exceptionally high number of somatic mutations compared with the TCGA esophageal cancer (ESCA) and ccRCC (KIRC).

HPD Tumors Contain Deleterious Mutations and Significantly Activated Oncogenic Signaling Pathways {#sec2.2}
-------------------------------------------------------------------------------------------------

To determine if certain genes were altered in both patients with HPD tumors, we searched for gene mutations that were common for the HPD tumors of both patients. Four genes were mutated in the post-treatment tumors of both patients: *NCOR2*, *GXYLT1*, *ZFPM1*, and *IGFBP2* ([Figure 2](#fig2){ref-type="fig"}A). There were 96 and 64 subject-specific nonsilent somatic mutations from 154 genes in post-treatment tumors of Patients 1 and 2, respectively ([Figures 2](#fig2){ref-type="fig"}B and 2C). The detailed information of these mutations are given in [Table S3](#mmc4){ref-type="supplementary-material"}.Figure 2Mutation Signatures of Post-anti-PD-1 Treatment Hyperprogressor Tumors(A--C) (A) Commonly mutated genes in the two hyperprogressor tumors, (B) specific mutated genes in Patient 1\'s hyperprogressor tumor, and (C) specific mutated genes in Patient 2\'s hyperprogressor tumor. See also [Figure S1](#mmc1){ref-type="supplementary-material"}, [Tables S1](#mmc2){ref-type="supplementary-material"} and [S3](#mmc4){ref-type="supplementary-material"}.

Bioinformatics analyses of these 161 mutations led to the identification of 11 potentially deleterious somatic variants in the HPD tumors, which were predicted to be "deleterious" by SIFT, "probably damaging" by PolyPhen-2, and "potentially associated with cancer" by FATHMM ([Table 2](#tbl2){ref-type="table"}). The 11 genes having these deleterious mutations were *TRPC4*, *POTEE*, *FBN2*, *KMT2C*, *FUT10*, *PQBP1*, *TSC2*, *MFSD6*, *CYP2D6*, *VHL*, and *RAD54B*. Of the 11 mutations, 10 were located at evolutionarily conserved sites, as predicted by GERP++ (scores \>2; [Table 2](#tbl2){ref-type="table"}). IPA (Ingenuity Pathway Analysis, Qiagen Inc., MD, USA), based on the 11 genes with the deleterious somatic mutations, identified a network involving these mutated genes that contributes to suppression of the *TP53* tumor suppressor and activation of *MYC*, *CCND1,* and *VEGF* oncogenes ([Figure S3](#mmc1){ref-type="supplementary-material"}). The mutated *TSC2* gene carrying a missense mutation, p.Y1611S, was in the center of this network and is linked to inhibition of the TP53 pathway and activation of the MYC, CCND1, and VEGF pathways ([Figure S3](#mmc1){ref-type="supplementary-material"}). TSC2 (also known as TUBERIN) is a tumor suppressor that negatively regulates cellular signaling networks that control cellular growth and proliferation ([@bib7]). The MuPIT interactive protein mutation analysis ([@bib33]) showed that the pY1611S mutation is located in the Rap/ran-GAP domain of the TSC2 protein, which is critical for the biological function of TSC2 ([Figure S4](#mmc1){ref-type="supplementary-material"}). Previous studies showed that TSC2 knockdown transforms mouse and human renal epithelial cells into neoplastic stem cells that can serially propagate upon re-inoculation in mice ([@bib7]). Together, it is reasonable to hypothesize that the deleterious p.Y1611S mutation could result in the loss of function of the TSC2 protein, which in turn will lead to uncontrolled proliferation of cancer cells in the HPD tumors that survive anti-PD-1 treatment.Table 2Characteristics of the 11 Deleterious Somatic Mutations in the HPD Tumors after Anti-PD-1 TreatmentGeneGenomic Position[a](#tblfn1){ref-type="table-fn"}Genomic MutationExonProtein AlterationPredicted Effect of Somatic Mutationsnp137ESP MAF[f](#tblfn6){ref-type="table-fn"}SIFT[b](#tblfn2){ref-type="table-fn"}PolyPhen-2[c](#tblfn3){ref-type="table-fn"}FATHMM[d](#tblfn4){ref-type="table-fn"}GERP++[e](#tblfn5){ref-type="table-fn"}TRPC4chr13: 38211734c.G2045A10p.R682HDeleterious (0.00)Probably damaging (0.999)Potentially associated with cancer (−2.83)6.06NANAPOTEEchr2: 132021334c.A2306T15p.Y769FDeleterious (0.00)Probably damaging (0.997)Potentially associated with cancer (−4.69)NANANAFBN2chr5: 127666313c.C4297T33p.R1433CDeleterious (0.00)Probably damaging (0.983)Potentially associated with cancer (−2.9)4.21NA7.70 × 10^−5^KMT2Cchr7: 151932981c.G2690C16p.R897PDeleterious (0.00)Probably damaging (0.995)Potentially associated with cancer (−2.21)5.1NANAFUT10chr8: 33246817c.G876T4p.K292NDeleterious (0.00)Probably damaging (1.00)Potentially associated with cancer (−4.75)3.42NANAPQBP1chrX: 48759773c.C256T4p.P86SDeleterious (0.00)Probably damaging (0.996)Potentially associated with cancer (−1.13)5.02NANATSC2chr16: 2137907c.A4832C37p.Y1611SDeleterious (0.02)Probably damaging (0.997)Potentially associated with cancer (−3.16)4.59NANAMFSD6chr2: 191301728c.G973A3p.G325RDeleterious (0.00)Probably damaging (0.998)Potentially associated with cancer (−2.42)6.07NANACYP2D6chr22: 42522990c.C1025T7p.T342MDeleterious (0.00)Probably damaging (0.996)Potentially associated with cancer (−2.26)4.06NANAVHLchr3: 10191479c.C349G2p.L117VDeleterious (0.00)Probably damaging (0.994)Potentially associated with cancer (−6.95)3.07NANARAD54Bchr8: 95411747c.T721G6p.F241VDeleterious (0.01)Probably damaging (0.996)Potentially associated with cancer (−3.01)5.55NANA[^2][^3][^4][^5][^6][^7][^8]

Based on the differentially expressed genes, IPA identified four significantly activated oncogenic signaling pathways in the HPD tumors after anti-PD-1 therapy compared with the pre-therapy tumors (p value \<0.01, *Z* score \>2, [Figure 3](#fig3){ref-type="fig"}A). They were the insulin growth factor (IGF)-1, extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK), Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT, and transforming growth factor (TGF)-β signaling pathways. A large number of genes in these oncogenic pathways were upregulated in the HPD tumors ([Figure 3](#fig3){ref-type="fig"}B). Such concerted gene expression changes may synergistically contribute to the generation of the HPD tumors after anti-PD-1 immunotherapy.Figure 3Activation of Oncogenic Pathways in HP Tumors after Anti-PD-1 Therapy(A and B) (A) Four oncogenic pathways were activated in the HP tumors. (B) The differentially expressed genes in these oncogenic pathways. Most of the genes were upregulated in the HP tumors after anti-PD-1 therapy. HP, hyperprogressive.

Clonal Evolution Was Detected in HPD Tumors after Anti-PD-1 Therapy {#sec2.3}
-------------------------------------------------------------------

The generation of WES data allowed us to quantify the mutant allele frequencies in all cases. Based on mutation clustering results, we inferred the identity of three clones having distinct sets of mutations (clusters) in pre-therapy tumors when compared with post-therapy HPD tumors of the two patients. Multiple mutation clusters (n = 3) were present in each of the pre-therapy tumors of the two HPD patients. In Patient 1, the post-anti-PD-1 treatment HPD tumor was associated with the outgrowth of new clone(s) represented by mutations in cancer-associated genes including *KMT2C*, *NCOR2*, *COL28A1*, *ING3*, *CAMKK2*, and *CARD8* ([Figures 4](#fig4){ref-type="fig"}A and 4C). The pre-therapy tumor clone(s) characterized by mutations in *APH1A, ARHGEF12, GPER1,* and *KIF14* genes was eliminated by anti-PD-1 treatment ([Figures 4](#fig4){ref-type="fig"}A and 4C). The clone(s) represented by mutations in the cancer genes *EP400*, *CUBN*, *SPP1*, *PHLPP2*, *PALB2*, *ERCC1*, *TFRC*, *MARK4*, and *MDM4* remained stable under the selection pressure of anti-PD-1 treatment ([Figures 4](#fig4){ref-type="fig"}A and 4C). In Patient 2, the post-anti-PD-1 treatment HPD tumor was associated with the evolution of new clone(s) represented by mutations in the cancer genes including *BAP1*, *CARD11*, *CBFA2T3*, *CYP2D6*, *PBRM1*, *TSC2*, and *VHL* ([Figures 4](#fig4){ref-type="fig"}B and 4D), whereas the pre-therapy tumor clone with mutations in *APC2, CDC27*, *OBSCN, PHLPP1,* and *SATB1* was not detectable after anti-PD-1 treatment ([Figures 4](#fig4){ref-type="fig"}B and 4D). Other clones, including those represented by mutations in *COL4A3*, *TTC40*, *NPHS1*, *UGT2A3*, *RYR1*, *AGGF1*, and *LANCL1,* remained stable before and after anti-PD-1 treatment ([Figures 4](#fig4){ref-type="fig"}B and 4D).Figure 4Illustration of Clonal Evolution of the Tumors before and after Anti-PD-1 Immunotherapy of the Two Patients with HPD(A--D) (A) Tumor clonal evolution in Patient 1 and (B) tumor clonal evolution in Patient 2. The gray area denotes the tumor clones unaffected by anti-PD-1 therapy, the green and blue areas denote the tumor clones diminishing and appearing due to anti-PD-1 therapy. The dynamics of these clones represented by changes in the variant allele frequency between the pre- and post-therapy tumors was plotted for (C) Patient 1 and (D) Patient 2. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

The tumor clonal evolution pattern associated with anti-PD-1 treatment was further validated by analyzing an independent dataset from a previous study, which conducted WES of paired baseline and relapsed tumors (before and after anti-PD-1 treatment) of four patients with melanoma ([@bib52]). As can be seen from [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}, all four melanoma cases demonstrated allele clusters after anti-PD-1 therapy. Variant allele frequencies (VAFs) of the Cluster 1 mutations were not significantly changed by PD-1 blockade; Cluster 2 mutations had reduced VAFs but were still prevalent in the relapsing tumor after PD-1 blockade; Cluster 3 mutations represented the newly evolved tumor clone(s) in the relapsing tumor after PD-1 blockade; Cluster 4 mutated genes represented the tumor clone(s) that diminished to undetectable levels after PD-1 blockade. These data are consistent with our own analysis of tumors from HPD patients before and after anti-PD-1 therapy.

HPD Tumors Demonstrate Decreased Immunogenicity Relative to Pre-therapy Tumors {#sec2.4}
------------------------------------------------------------------------------

Since anti-PD-1 treatment renders its effects on tumors in a manner completely dependent on immunity, we investigated whether HPD tumors demonstrated changes in their capacity to elicit productive immune reactions using an *in silico* immunophenogram approach ([@bib6]). The results showed that HPD tumors had much smaller immunophenoscores compared with the pre-therapy tumors for both patients ([Figure 5](#fig5){ref-type="fig"}). Expression of HLAs (human leukocyte antigens) was downregulated in the post-therapy HPD tumors compared with the pre-therapy tumors, whereas checkpoint genes were upregulated in the HPD tumors ([Figure 5](#fig5){ref-type="fig"}). These changes resulted in the overall reduction of immunophenoscores in HPD tumors. Consistent with results from the immunophenogram analysis, the differential expression analysis showed that seven genes involved in antigen processing were downregulated in the HPD tumors, i.e., *B2M*, *HLA-B*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DRA*, *HLA-E*, and *HLA-F* ([Figure 6](#fig6){ref-type="fig"}A). In addition, eight genes encoding immune checkpoints or modulators were upregulated in the HPD tumors, i.e., *CTLA4*, *KDR*, *CD96*, *CD70*, *TNFRSF18*, *TNFRSF25*, *BTNL2*, and *TNFRSF8* ([Figure 6](#fig6){ref-type="fig"}A). Changes in expression of these immune-related genes were likely contributors to the weakened immunogenicity of the HPD tumors.Figure 5Immunophenoscores of the Hyperprogressor versus Non-hyperprogressor Tumors of the Two Patients Subject to Anti-PD-1 ImmunotherapyHLAs were downregulated in the HPD tumors compared with the pre-therapy tumors (shown in the upper left quadrant termed MHC), whereas checkpoints were upregulated in the HPD tumors (shown in the lower left quadrant termed CP). These changes resulted in the overall reduction of immunophenoscores in the HPD tumors resistant to anti-PD-1 immunotherapy. See also [Figure S14](#mmc1){ref-type="supplementary-material"}.Figure 6Changes in the Expression of Critical Immune-Related Genes and the Activity of Immune Cell Populations Contribute to Decreased Immunogenicity in the Post-α-PD-1 HPD Tumors(A) Seven genes involved in antigen processing were downregulated, whereas eight genes encoding immune checkpoints or modulators were upregulated in hyperprogressor tumors.(B) The activity of eight immune cell populations were weakened and three were strengthened, as detected by GSVA method.See also [Figure S14](#mmc1){ref-type="supplementary-material"}.

Immune Cell Signatures in HPD Tumors Are Predominately Immunosuppressive {#sec2.5}
------------------------------------------------------------------------

Previous studies have characterized the signature genes of 28 immune cell populations critical to immune responses across multiple cancers ([@bib1], [@bib6]). Using GSVA (Gene Set Variation Analysis) ([@bib17]), we evaluated the immune cell landscape in the HPD tumors from our two patients. We identified that the activities of eight immune cell populations were significantly decreased in the HPD tumors after anti-PD-1 treatment ([Figure 6](#fig6){ref-type="fig"}B). These populations were monocytes, central memory CD4 T cells, immature dendritic cells, CD56dim NK (natural killer) cells, NK cells, gamma-delta (γδ) T cells, activated dendritic cells, and follicular helper T cells, most of which are linked to functional tumor clearance. In addition, the activities of three immune cell populations, i.e., neutrophils, activated B cells, and neutrophil-like myeloid-derived suppressor cells (MDSC), were upregulated in the hyperprogressors ([Figure 6](#fig6){ref-type="fig"}B). These data suggest that the depletion of monocytes, certain types of T cells, NK cells, and dendritic cells may contribute to the ability of HPD tumors to escape immune surveillance. Furthermore, the upregulated neutrophil population as well as the neutrophil-like MDSC (i.e., the MDSC subpopulation with neutrophil signature gene expression) ([@bib53]) may also contribute to the immune evasion of HPD tumors since these cell populations have been implicated in generating a milieu that attenuates immune responses in the tumor microenvironment ([@bib10], [@bib32], [@bib38], [@bib46], [@bib53]).

ILC3 Innate Lymphocytes Are Upregulated in HPD Tumors {#sec2.6}
-----------------------------------------------------

Recent studies have revealed the importance of innate lymphoid cells (ILCs) in homeostasis and inflammation of tumors ([@bib3], [@bib48]). Although three main populations of ILCs, ILC1, ILC2, and ILC3, have been categorized based on their transcription factor profiles and secreted cytokines ([@bib41]), little is known about their roles in carcinogenesis and immunotherapy resistance. To evaluate ILCs in HPD tumors, we analyzed the transcriptional levels of the marker genes characteristic of the ILC1, ILC2, and ILC3 populations ([@bib3], [@bib48]). GSEA ([@bib42]) showed that the ILC3 marker genes were significantly enriched among the top upregulated genes in the HPD tumors after anti-PD-1 treatment ([Figures 7](#fig7){ref-type="fig"}A and 7B). In contrast, the ILC1 and ILC2 marker genes were not enriched in either the up- or downregulated genes in the HPD tumors ([Figure S7](#mmc1){ref-type="supplementary-material"}). These data suggest that the ILC3 population is activated in HPD tumors. To validate this finding, we analyzed the RNA-seq data from other studies that evaluated tumor changes in response to anti-PD-1 therapies. Analysis of the transcriptomes of responding (n = 15) and nonresponding (n = 13) pre-treatment melanoma tumors from the patients subject to PD-1 blockade ([@bib19]) showed that ILC3 marker genes were commonly upregulated in the melanoma tumors resistant to anti-PD-1 therapy ([Figure 7](#fig7){ref-type="fig"}C). Based on the RNA-seq data of the Kras^G12D^ mouse model, we also found that there were a large number of ILC3 marker genes significantly upregulated in murine lung adenocarcinoma tumors that were resistant to anti-PD-1 therapy when compared with untreated tumors ([@bib24]) ([Figure 7](#fig7){ref-type="fig"}D). These results are concordant with our HPD RNA-seq data, suggesting that enrichment of the ILC3 population in the HPD tumors may be a characteristic feature of tumors that are insensitive to anti-PD-1. This finding is consistent with the previous report that ILC3 lymphocytes contribute to the initiation and progression of cancers ([@bib9]). The mechanistic connection between ILC3 population and anti-PD-1 therapy effect is unknown. However, it was reported that ILC3 may promote the growth of mutant tumor cells that express the receptors needed for oncogenic pathways ([@bib9], [@bib23]). Our and others\' data ([@bib35]) suggested that anti-PD-1 therapy increased tumor mutation burden in patients with cancer with hyperprogressive or progressive tumor phenotype. Therefore, activated ILC3 cell population may be required for the promotion of the growth of more mutant cells in the patients with cancer with HPD or PD subjected to anti-PD-1 therapy.Figure 7The ILC3 Population Was Activated in the HPD Tumors after Anti-PD-1 Therapy(A--D) (A) GSEA showed that ILC3 marker genes were significantly enriched in the top upregulated genes in HPD tumors resistant to anti-PD-1 therapy. (B) Most of the differentially expressed ILC3 marker genes in the HPD tumors resistant to anti-PD-1 treatment were upregulated. (C) A higher percentage of ILC3 marker genes were upregulated in the nonresponding melanoma tumors resistant to anti-PD-1 therapy based on the analysis of data from an independent study in humans. (D) Upregulation of ILC3 marker genes comparing anti-PD-1-treatment-resistant mouse tumors with untreated tumors in the Kras^G12D^ mouse model.

Pro-inflammatory Pathways Were Activated in the Pre-therapy Tumors of Patients with HPD and Further Activated by Anti-PD-1 Therapy {#sec2.7}
----------------------------------------------------------------------------------------------------------------------------------

PD-1 has been demonstrated to inhibit excessive inflammatory responses during infection in mouse models ([@bib25]). To identify the inflammatory changes in HPD tumors, we evaluated changes in inflammatory-related genes included in the "hallmark inflammatory" gene set ([@bib28], [@bib27]). To characterize the inflammation activity in post-anti-PD-1 treatment HPD tumors versus pre-treatment tumors, we again utilized GSVA, which identified four founder datasets of inflammation pathways that were significantly enhanced in the HPD tumors after anti-PD-1 treatment ([Figure 8](#fig8){ref-type="fig"}A). In each of these four pro-inflammatory datasets, many more genes were up- than downregulated ([Figures 8](#fig8){ref-type="fig"}B--8E), suggesting an overall pro-inflammatory trend after anti-PD-1 treatment.Figure 8Activation of Inflammatory Pathways in the HPD Tumors after Anti-PD-1 Treatment(A) GSVA identified the activation of four founder datasets of inflammation pathways.(B) Differentially expressed genes in the inflammatory signature of RESPONSE_TO_CHEMICAL_STIMULUS; (C) Differentially expressed genes in the inflammatory signature of KEGG_CHEMOKINE_SIGNALING_PATHWAY; (D) Differentially expressed genes in the inflammatory signature of INFLAMMATORY_RESPONSE; (E) Differentially expressed genes in the inflammatory signature of CHEMOKINE_ACTIVITY. In each of the four pro-inflammatory datasets from (B--E), there were much more upregulated than downregulated genes. See also [Figure S8](#mmc1){ref-type="supplementary-material"}.

For comparison, we analyzed the gene expression data of tumor samples from the [GSE52562](ncbi-geo:GSE52562){#intref0015} dataset before anti-PD-1 treatment ([@bib50]). This dataset included two potential HPD patients whose progression-free survival (PFS) was less than 2 months post-pidilizumab treatment (SAMPLE.25 and SAMPLE.5 in [Table S4](#mmc1){ref-type="supplementary-material"}) and four responsive patients whose PFS was more than 2 years (24 months) after treatment (SAMPLE.23, SAMPLE.19, SAMPLE.13, and SAMPLE.17 in [Table S4](#mmc1){ref-type="supplementary-material"}). This analysis showed that the tumors of HPD patients have elevated inflammation pathway activity (mainly chemokine activity) even before anti-PD-1 therapy when compared with tumors from non-HPD patients ([Figure S8](#mmc1){ref-type="supplementary-material"}). These and our data collectively suggested that anti-PD-1 therapy further boosts the pre-existing high levels of inflammation in patients who subsequently develop HPD in ways that are not conducive to promoting tumor rejection.

HPD-Associated Gene Expression Signature {#sec2.8}
----------------------------------------

Based on the pre-therapy tumor expression data of Dataset_1 (See [Transparent Methods](#mmc1){ref-type="supplementary-material"}), we developed a 121-gene set to differentiate HPD patients from non-HPD patients ([Figure S9](#mmc1){ref-type="supplementary-material"}, [Table S5](#mmc1){ref-type="supplementary-material"}). The effectiveness of this 121-gene classifier in the identification of HPD patients was tested using the pre-therapy tumor expression data from Dataset_2 (See [Transparent Methods](#mmc1){ref-type="supplementary-material"}). This classifier had an area under curve (AUC) value of 0.91 (95% confidence interval \[CI\], 0.87--0.96), a sensitivity of 71% (95% CI, 51%--87%), and a specificity of 93% (95% CI, 80%--99%) in predicting HPD patients in Dataset_2 ([Figure 9](#fig9){ref-type="fig"}A). Kaplan-Meier analysis of TCGA data showed that the 121-gene expression signature can significantly separate low-risk group from high-risk group in the 13 major types of cancers including melanoma (SKCM), glioma, and carcinomas of the esophagus (ESCA), stomach (STAD), breast (BRCA), kidney (KIRC), bladder (BLCA), liver (LIHC), head and neck (HNSC), lung (LUAD and LUSC), colon (COAD), and pancreas (PAAD) ([Figures 9](#fig9){ref-type="fig"}B--9D and [S10--S12](#mmc1){ref-type="supplementary-material"}). This panel was able to identify extremely high-risk groups in ESCA, COAD, and PAAD ([Figures 9](#fig9){ref-type="fig"}B--9D).Figure 9Performance of the 121-Gene Set Classifier in the Validation Dataset and Its Effectiveness in the Prognosis of Worse Survival Outcome in the TCGA Datasets(A--D) (A) Receiver operating characteristic (ROC) curves shown for separating HPD patients from non-HPD patients in the validation dataset (Dataset_2, 21 HPD versus 30 non-HPD patients, AUC = 0.91 \[95% CI, 0.87--0.96\]); Kaplan-Meier analysis showed that the 121-gene set classifier can separate significantly low- and high-risk groups in all of the 13 major TCGA cancers, of which the top three cancers with greatest hazard ratios (HRs) were shown in (B) ESCA (HR = 100.1, 95% CI, 23.1--433.6); (C) COAD (HR = 17.5, 95% CI, 7.4--40.9), and (D) PAAD datasets (HR = 16.0, 95% CI, 8.8--29.0). See also [Figures S9--S12](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Checkpoint blockade with anti-PD-1 antibodies has resulted in excellent responses in a subset of patients with cancer. However, there is a sizable proportion of patients with cancer who do not respond to anti-PD-1 treatment, with a subset of these patients developing hyperprogression with accelerated tumor growth after anti-PD-1 immunotherapy ([@bib5], [@bib22]). Currently, there is a lack of systematic genome studies to identify the genes or immune factors that predict resistance to immune checkpoint inhibition or HPD in response to anti-PD-1 treatment. In this study, we utilized WES and RNA-seq approaches to identify the mutation spectrum and gene expression profiling changes in HPD tumors when compared with pre-therapy tumors. We also performed pathway and tumor immunogenicity analyses based on the RNA-seq data. Finally, we combined our data with publicly available datasets and developed an HPD gene expression signature capable of predicting patients unlikely to respond to anti-PD-1.

The mutation analysis highlighted 11 genes with deleterious mutations in the HPD tumors after anti-PD-1 therapy ([Table 2](#tbl2){ref-type="table"}). Most of these genes have not been adequately studied in the context of cancer before. However, a query of this 11 mutated gene set in the cBioPortal website (<http://www.cbioportal.org/>) ([@bib4], [@bib11]) showed that this gene set has somatic mutations or copy number aberrations (CNAs) in 8,887 (22%) of the 41,320 sequenced patients. The alterations of these 11 genes were most frequent in the six major cancer types with an alteration frequency \>30% ([Figure S13](#mmc1){ref-type="supplementary-material"}), i.e., prostate cancer (70.8% tumor samples had mutations or CNAs in at least one of the 11 genes), melanoma (50.2% altered), renal cell carcinoma (45.3% altered), brain cancer (33.3% altered), breast cancer (31.1% altered), and colorectal adenocarcinoma (31.0% altered). These data support the cancer linkage to these 11 genes, the mutations of which could contribute to the tumor hyperprogressive phenotype.

Among the 11 genes, some have tumor suppressive properties, good examples being *TSC2* and *VHL*. Inactivating mutations in *TSC2* that encode the protein tuberin lead to constitutive activation of mTOR kinase through the Rheb-GTP signaling axis ([@bib30], [@bib54]), which in turn induces cell growth, motility, invasion, and development of tumors ([@bib12], [@bib13]). These outcomes were consistent with our observation that the deleterious pY1611S mutation in the key Rap/ran-GAP domain of the TSC2 protein ([Table 2](#tbl2){ref-type="table"}, [Figure S4](#mmc1){ref-type="supplementary-material"}) occurred in the hyperprogressive tumors after anti-PD-1 therapy. We also found that the *VHL* gene had a deleterious mutation---pL117V---in the ccRCC hyperprogressive tumors after anti-PD-1 treatment ([Table 2](#tbl2){ref-type="table"}). *VHL*, located on chromosome 3p25, is a major tumor suppressor gene involved in ccRCC oncogenesis ([@bib15]). Interestingly, a recent study found that PD-L1 expression was associated with dense PD-1 expression and wild-type *VHL* ccRCC, but not with mutated/inactivated *VHL* ccRCC ([@bib21]). Therefore, only the patients with ccRCC with wild-type *VHL* may benefit from immunotherapies inhibiting PD-L1/PD-1 ([@bib21]). In our case, we found that only the post-anti-PD-1 therapy hyperprogressive ccRCC tumor had detectable deleterious *VHL* mutation, but the pre-therapy ccRCC tumor did not. This suggested that the selection pressure of anti-PD-1 therapy eliminated most of the wild-type *VHL* ccRCC cells but had little effect on cells with mutated *VHL* ccRCC, such that these mutated cells were highly enriched in the post-therapy HPD tumors. This has significant implications in that it suggests that ccRCC cells with an altered/mutated *VHL* gene may be a key factor leading to HPD after anti-PD-1 therapy.

The pre- and post-treatment tumors in this study were acquired through biopsy from the primary lesion. After anti-PD-1 therapy, the initial minor subclones of somatic mutations could be boosted by the treatment and expanded in the tumor samples of the two HPD patients as shown in [Figure 4](#fig4){ref-type="fig"}, which contributed to the tumor heterogeneity that may account for changes in the mutational and/or expression landscape. Clonal evolution analysis ([Figure 4](#fig4){ref-type="fig"}) indicates that HPD tumor-specific mutations in *TSC2* and *VHL* along with mutations in a number of other cancer genes including *KMT2C*, *NCOR2*, *COL28A1*, *ING3*, *CAMKK2*, *CARD8, BAP1*, *CARD11*, *CBFA2T3*, *CYP2D6*, and *PBRM1* could be significant to the progression of nonaggressive pre-therapy tumors to the hyperprogressive state after anti-PD-1 treatment. [Figure S3](#mmc1){ref-type="supplementary-material"} showed that the mutated *KMT2C*, *TSC2*, *VHL*, and *CYP2D6* genes were involved in the gene-gene interaction network leading to suppression of the TP53 pathway activity. Previous studies showed that *KMT2C (MLL3)* co-activates *TP53*, whereas *KMT2C* levels decrease during cancer progression, which correlates with distinct clinical stages ([@bib8], [@bib26], [@bib34]). These results are consistent with our observations in HPD tumors after anti-PD-1 treatment.

Our RNA-seq data revealed that the IGF-1, ERK/MAPK, PI3K/AKT, and TGF-β signaling pathways were activated in the HPD tumors after anti-PD-1 therapy ([Figure 3](#fig3){ref-type="fig"}). Recent studies have found that TGF-β signaling may play an important role in resistance to immunotherapy. For example, Mariathasan et al. reported that lack of response to anti-PD-L1 antibody was associated with TGF-β signaling in fibroblasts and the exclusion of CD8^+^ T cells, indicating that TGF-β-mediated stromal remodeling restricts T cell infiltration to suppress antitumor immunity and that TGF-β inhibition may enhance the efficacy of immune checkpoint blockade ([@bib29]). In parallel, Tauriello et al. found that single-agent PD-1/PD-L1 inhibition had little effect, but co-targeting TGF-β produced a robust antitumor immune response that could prevent the development of metastasis and eliminate established metastases in a mouse model ([@bib43]). Collectively, these studies indicate that inhibiting TGF-β could significantly improve the efficacy of anti-PD-1/anti-PD-L1 treatment ([@bib29], [@bib43]). Herein, our data suggest that enhanced TGF-β signaling could also contribute to the development of HPD after anti-PD-1 therapy. Therefore, inhibiting TGF-β signaling may also help prevent the development of HPD in response to anti-PD-1 treatment. Another interesting finding is the activation of PI3K/AKT in HPD tumors. A recent study demonstrated that the activity of PI3K/AKT signaling was crucial for lymphomas with PD-1 deletion ([@bib49]). Therefore, when the tumors are exposed to anti-PD-1 therapy, elevated PI3K/AKT signaling may be another important mechanism for the survival, progression, or even hyperprogression of the tumor cells.

The HPD tumors had reduced tumor immunogenicity when compared with the pre-therapy tumors. Such reduction may be caused by downregulation of antigen-processing genes, including several *HLA* genes and *B2M*, and upregulation of certain immune checkpoint or modulator genes other than PD-1/PD-L1 ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). In the context of studying 28 immune cell populations critical to pan-cancer immunogenomics ([@bib1], [@bib6]), we found that the activity of eight immune cell populations were weakened and two were strengthened in the HPD tumors. The weakened immune cell populations including monocytes, CD4 helper T cells, dendritic cells, and NK cells may contribute to the ability of HPD tumors to escape immune surveillance. The enhanced cell populations such as neutrophils are known to have a number of pro-tumor properties ([@bib10], [@bib32], [@bib38], [@bib46]), thus the increase in neutrophil activity in HPD tumors was not surprising.

The two patients developed HPD after anti-PD-1 therapy, indicating the adverse immunity changes that may result in an immunosuppressive environment. The decreased portion of immune cell phenotypes after anti-PD-1 therapy led us to speculate whether anti-PD-1 therapy contributed to accelerated AICD (activation-induced cell death) in these two patients. To test this hypothesis, we applied the GSVA approach to the apoptosis gene sets collected in the MSigDB database ([@bib27]). It can be seen that five apoptosis gene sets were activated in the two patients after anti-PD-1 therapy ([Figure S14](#mmc1){ref-type="supplementary-material"}A), of which 27 apoptotic genes including marker genes in caspase/bcl2 pathways (*CASP3*, *CASP7*, *BNIP2*, and *BNIP3L*) were significantly upregulated ([Figure S14](#mmc1){ref-type="supplementary-material"}B). This indicated that the accelerated AICD may occur in the anti-tumor activating lymphocytes, which accounted for the decreased portion of immune cell phenotypes and enhanced immunosuppressive environment after anti-PD-1 therapy.

So far, cancer immunotherapies have largely focused on T lymphocytes. However, ILCs could also play important roles in the immune response. ILCs were classified into cytotoxic ILCs, such as NK cells, and helper-like ILCs, such as the ILC1, ILC2, and ILC3 subsets. Much of the role of ILCs other than NK cells in cancer and immunotherapy remain elusive. ILCs might represent promising targets in the context of cancer therapy because they are endowed with potent immunomodulatory properties. In the present study, we analyzed the dynamic changes in the activity of ILC populations associated with anti-PD-1 therapy. This represents the first study analyzing the ILC populations in hyperprogressive tumors after anti-PD-1 therapy. Although ILC1 and ILC2 subsets did not show significant changes according to GSEA ([Figure S7](#mmc1){ref-type="supplementary-material"}), the ILC3 population was activated in HPD tumors compared with pre-therapy tumors ([Figure 7](#fig7){ref-type="fig"}). Among the three subsets of ILCs, the role of ILC3 is gaining increased interest for its potential tumor-promoting activities. ILC3 that produces interleukin (IL)-22 has also been shown to promote tumor growth mediated via STAT3 activation ([@bib23]). Another study showed that ILC3 promoted lymphatic metastasis by modulating the local chemokine milieu of cancer cells ([@bib20]). ILC3 may also promote tumor formation and progression by suppressing T cell responses ([@bib47]). It had been shown that intestinal ILC3 cells limit T cell responses and induce T cell death via outcompeting T cells for IL-2 ([@bib18]). We observed upregulated expression of ILC3 marker genes by anti-PD-1 immunotherapy in the two HPD patients, which may contribute to the suppression of T cell responses or the induction of T cell death. Our findings were in line with those of previous studies, indicating that inhibiting ILC3 may complement anti-PD-1 treatment to reduce the likelihood of developing hyperprogressive tumors after the therapy.

It is worth mentioning that IL-22 expression was not detected in the before and after anti-PD-1 treatment FFPE samples of the two patients, which may be due to the influence of the degradation of the RNA samples from the FFPE specimens on gene expression study. However, previous studies have defined a large group of marker genes whose expressions were characteristic of the ILC3 cell population ([@bib3], [@bib48]). For example, the ILC3 cells were defined by using a repertoire of around 400 genes ([@bib3], [@bib48]), which became the basis of our analyses on ILC3 cells. Therefore, we analyzed the expression pattern changes of these marker genes to study the dynamic changes of ILC cell populations in response to the anti-PD-1 immunotherapy in the tumors of the HPD patients ([Figures 7](#fig7){ref-type="fig"} and [S7](#mmc1){ref-type="supplementary-material"}).

Previous research showed that PD-1-deficient mice were extraordinarily sensitive to tuberculosis and had much shorter survival times compared with wild-type mice ([@bib25]). This sensitivity results from the need for the PD-1 pathway to control excessive inflammatory responses to tuberculosis infection in the lungs of mice ([@bib25]). This led us to hypothesize that the PD-1 pathway may also be required to control excessive inflammatory responses in patients susceptible to HPD. If anti-PD-1 therapy is administered to HPD patients, it may contribute to tumor growth by further upregulating inflammatory pathway activities. The analyses of our data and those of others ([@bib50]) confirmed this hypothesis by showing that anti-PD-1 therapy can further boost the pre-existing high levels of inflammation in HPD patients, and thus contribute to the hyperprogressive phenotype ([Figures 8](#fig8){ref-type="fig"} and [S8](#mmc1){ref-type="supplementary-material"}).

On the basis of genome-wide expression data of tumors from our study, and two publicly available datasets (before anti-PD-1 therapy) ([@bib35], [@bib50]), we identified and validated a 121-gene expression signature that can distinguish HPD patients from non-HPD patients. This may have significant clinical predictive value to identify patients who are suitable for anti-PD-1/anti-PD-L1 immunotherapy. Having validated this gene set, we examined whether there exists any mechanism that might explain its association with HPD. Interestingly, most of these genes (70 of 121) belonged to gene sets that we identified as significant to different aspects of the HPD tumors in our samples. Specifically, these genes could be classified into the following six categories that were described above as important contributors to the HPD phenotype ([Figure S9](#mmc1){ref-type="supplementary-material"}): (1) somatic mutated gene sets; (2) oncogenic pathways of IGF-1, ERK/MAPK, PI3K/AKT, and TGF-β; (3) immune checkpoint genes; (4) ILC3 population marker genes; (5) marker genes for other immune populations like monocytes, CD4 T cells, and dendritic cells; and (6) differentially expressed genes in post-anti-PD-1 HPD tumors versus pre-anti-PD-1 non-HPD tumors. Thus, a significant portion of these HPD signature genes could be involved in the critical biological processes important to tumor evolution, infiltrated immune cells, and tumor-microenvironment interactions. However, although we validated the 121-gene set, more patient cohorts subjected to anti-PD-1 therapy that contain HPD and non-HPD patients are needed for prospective validation.

To better define HPD, especially to differentiate HPD from intermediate and/or late tumor progression, we compared the mutational and gene expression of the two original samples in our study with the pre-treatment tumor samples of the four patients (\#28, \#9, \#26, \#38) who developed intermediate and/or late tumor progression ([Table S6](#mmc1){ref-type="supplementary-material"}). Mutation analysis showed that 40 cancer genes had nonsilent somatic mutations in the original tumors of the HPD patients but no mutations in the tumors of the patients whose tumor progression was intermediate and/or late ([Figure S15](#mmc1){ref-type="supplementary-material"}). These genes include, for example, *MUC13*, *MUC6*, *APC2*, *ARID2*, *CDK4*, *EP400*, *MARK4*, *MDM4*, *MUC2*, *NOTCH1*, and *SLIT2*. Previous research demonstrated that *MDM4* alteration was significantly associated with hyperprogression in patients subjected to immunotherapy ([@bib22]), which was consistent with our results. We tabulated the information of these 40 HPD-associated cancer genes in [Table S7](#mmc1){ref-type="supplementary-material"}. At the transcriptome level, GSVA identified four gene sets from the MsigDB database that were significantly altered in the tumors of HPD patients compared with the patients with intermediate and/or late tumor progression. These gene sets were: HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY, HALLMARK_DNA_REPAIR, HALLMARK_ADIPOGENESIS, and SINGH_KRAS_DEPENDENCY_SIGNATURE. The first three pathways, i.e., the reactive oxygen species pathway, the DNA repair pathway, and the adipogenesis pathway, were significantly inhibited, whereas the KRAS signaling pathway was significantly activated in the tumors of HPD patients relative to the patients with intermediate and/or late tumor progression ([Figure S16](#mmc1){ref-type="supplementary-material"}A). The corresponding gene expression changes of the above significantly altered pathways were also shown ([Figure S16](#mmc1){ref-type="supplementary-material"}B). Together, these mutational and transcriptional changes of the tumors between the HPD and the intermediate/late tumor progression patients may contribute to the better characterization of the HPD condition.

Overall, our comprehensive analysis of HPD tumors after anti-PD-1 therapy and pre-therapy tumors identified the genomics and immune factors contributing to the hyperprogression phenotypes, such as deleterious somatic mutations in important tumor suppressors such as *TSC2* and *VHL*, downregulated antigen-processing genes, and upregulated immune checkpoints or modulators other than PD-1/PD-L1. We also identified immune cell populations with significant activity changes in the HPD tumors; particularly the ILC subset, ILC3, was found to be activated in the HPD tumors after anti-PD-1 treatment. A gene expression signature for HPD tumors was also identified and validated using our samples and publicly available datasets. Our findings may contribute to understanding the mechanisms of the development of HPD after anti-PD-1 treatment, which is important to identify patients at high risk of developing HPD.

Limitations of Study {#sec3.1}
--------------------

In this study, we analyzed the genomics, transcriptomics, and immunogenicity of two patients subjected to anti-PD-1 immunotherapy who developed hyperprogression after the treatment. We acknowledged that the patient sample size was small in this study. This is because the majority of the patients either did not develop hyperprogression or had the pseudo-hyperprogressive phenotype after checkpoint immunotherapy. Further larger patient samples involving more HPD patients treated with anti-PD-1 are needed to validate and extend our findings. Another limitation is that we only profiled HPD tumor sample one time upon hyperprogression after anti-PD-1 immunotherapy and did not collect post-hyperprogression tumor samples at later time points. This design rendered us unable to investigate whether the associated immunosuppressive profiles of HPD tumors remain as such even at later time points. However, our study is innovative in terms of analyzing both the before- and after-immunotherapy DNA/RNA samples of the HPD patients and serves as the starting point for similar studies that are lacking in the field.

Currently, the two outside datasets we used in the manuscript were the only ones that have the transcriptome-level gene expression data available publicly for us to develop a gene expression profile for HPD ([@bib35], [@bib50]). Based on the available data, we characterized a 121-gene expression profile to differentiate HPD patients from non-HPD patients in both the datasets ([@bib35], [@bib50]) with high AUC values and high sensitivity and specificity as described in the manuscript. More HPD patients with well-profiled transcriptome data and detailed clinical information related to the anti-PD-1 treatment are needed to verify our gene expression signature.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Software Availability {#appsec3}
==============================

The WES and RNA-seq raw sequence reads data from the before and after anti-PD-1 immunotherapy FFPE samples from the two cancer patients (4 FFPE samples) have been deposited in the Sequence Read Archive under accession number of PRJNA503522.
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